Clinical trial
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and…
NCT00292084 · BioWest Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00292084 |
|---|---|
| Title | An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection |
| Official title | A Phase II, Multi-Center, Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With or Without Ribavirin, for an Additional 36 Weeks |
| Lead sponsor | BioWest Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Celgosivir |
| Enrollment | 60 |
| Start date | Feb 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Feb 15, 2006 |
| Last update posted | Jan 21, 2008 |
| Countries | Canada |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: